Cue Biopharma Inc Share Price

NASDAQ: CUE

Small Cap

$0.74

(+0.01%)

Live

as on September 17, 2025 at 12:27 am IST

$₹

Cue Biopharma Inc Stock Performance

as on September 17, 2025 at 12:27 am IST

Day's Low
Day's High
$0.72
Day's Price Range
$0.78
$0.74
2.70%
Downside
5.41%
Upside
52 Week's Low
52 Week's High
$0.45
52-Week Price Range
$1.99
$0.74
39.19%
Downside
168.80%
Upside

Cue Biopharma Inc share price movements today

Previous Close: $0.74
Open: $0.77
Volume: 845.2K
Day's Low - High: $0.72 - $0.78
52 Week Low - High: $0.45 - $1.99

Cue Biopharma Inc Historical Returns

1 Month Return: -10.42 %
3 Month Return: + 25.41 %
1 Year Return: + 31.33 %
3 Year Return: -75.58 %
5 Year Return: -95.8 %

Cue Biopharma Inc Stock Fundamentals & Key Indicators

Check Cue Biopharma Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$57.0M

EPS (TTM)

-0.415

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.75

Industry PE ratio

-3.947831325301205

P/B Ratio

PEG Ratio

EBITDA

-39.1M

Revenue (TTM)

8.3M

Profit Margin

0.00%

Return On Equity TTM

0.00%

Cue Biopharma Inc Stock Valuation

Track how Cue Biopharma Inc P/E has moved over time to understand its valuation trends.

Cue Biopharma Inc in the last 5 years

Overview
Trends

Lowest (0.00x)

September 16, 2025

Industry (-3.95x)

September 16, 2025

Today (-0.75x)

September 16, 2025

Highest (-0.79x)

September 30, 2024

LowHigh

Today’s Price to Earnings Ratio: -0.75x

Cue Biopharma Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Cue Biopharma Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Cue Biopharma Inc	BUY	$57.0M	-95.8%	-0.75	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$61.1B	251.26%	-505.15	-12.96%
Beone Medicines Ltd	NA	$38.7B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$101.2B	47.46%	28.09	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$59.6B	0.6%	14.1	31.37%

Stock Returns calculator for Cue Biopharma Inc Stock including INR - Dollar returns

The Cue Biopharma Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Cue Biopharma Inc investment value today

Current value as on today

₹1,37,010

Returns

₹37,010

(+37.01%)

Returns from Cue Biopharma Inc Stock

₹32,143 (+32.14%)

Dollar Returns*

₹4,867 (+4.87%)

Analyst Recommendation on Cue Biopharma Inc Stock

Based on 9 analysts

BUY

88.89%

Buy

11.11%

Hold

0.00%

Sell

Based on 9 analysts, 88.89% of analysts recommend a 'BUY' rating for Cue Biopharma Inc. Average target price of $4

Cue Biopharma Inc Share Price Target

Get share price movements and forecasts by analysts on Cue Biopharma Inc.

What analysts predicted

81.5%UPSIDE

Target Price

Current Price

$0.74

Analyzed by

9 Analysts

Target

$4.00

Cue Biopharma Inc target price $4, a slight upside of 81.5% compared to current price of $0.74. According to 9 analysts rating.

Cue Biopharma Inc Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	0	1	2	1	1	2	3	1	0	2
Gross Profit	0	0	-33	0	1	2	3	1	0	2
Operating Income	-13	-13	-11	-13	-12	-10	-8	-9	-12	-8
EBITDA	-11	-12	-9	-12	-11	-9	-7	-9	-11	-8
Interest Expense	0	0	0	0	0	0	0	0	0	0
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-13	-13	-11	-13	-12	-10	-8	-9	-12	-8
Income Tax Expense	0	0	0	0	0	-	-8	-	-	-
Net Income	-13	-13	-11	-13	-12	-10	-8	-9	-12	-8
Net Profit Margin	-7063.10%	-954.05%	-524.05%	-737.73%	-719.10%	-382.66%	-259.59%	-602.54%	-2911.40%	-287.14%

Cue Biopharma Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	-	-	-	1	3	3	14	1	5	9
Gross Profit	0	0	0	-27	3	-30	14	0	-32	9
Operating Income	-1	-7	-23	-38	-36	-45	-43	-53	-52	-41
EBITDA	-1	-7	-22	-37	-31	-43	-45	-50	-46	-37
Interest Expense	-	-	-	-	5	0	1	0	1	0
Depreciation	-	-	0	0	5	1	-1	1	3	2
Income Before Tax	-1	-7	-23	-38	-36	-44	-43	-53	-50	-40
Income Tax Expense	-	-	-	0	0	0	0	0	3	-40
Net Income	-1	-7	-23	-38	-36	-44	-44	-52	-50	-40
Net Profit Margin	0.00%	0.00%	0.00%	-3411.53%	-1061.25%	-1419.79%	-295.56%	-4239.87%	-924.10%	-437.97%

Cue Biopharma Inc Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-13	-11	-13	-12	-10	-8	-9	-12	-8
Operating Cash Flow	-10	-7	-10	-9	-9	-7	-9	-8	-3
Investing Cash Flow	5	5	-	0	0	0	0	0	0
Financing Cash Flow	2	4	4	2	-1	9	0	-1	17
Change in Cash	-3	1	-6	-7	-11	2	-9	-9	14

Cue Biopharma Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-7	-23	-38	-36	-44	-44	-53	-50	-40
Operating Cash Flow	-5	-12	-26	-30	-32	-38	-41	-39	-36
Investing Cash Flow	0	-1	-20	3	4	9	-24	25	0
Financing Cash Flow	15	62	4	50	58	19	53	11	10
Change in Cash	8	48	-42	23	30	-10	-12	-3	-26

Global Institutional Holdings in Cue Biopharma Inc

Funds	Holdings
Bleichroeder LP	6.63%
Vanguard Group Inc	3.07%
Geode Capital Management, LLC	0.92%
BlackRock Inc	0.84%
Robertson Stephens Wealth Management, LLC	0.64%

See all

Insights on Cue Biopharma Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, -12.25M → -8.48M (in $), with an average increase of 44.5% per quarter
POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 421.0K → 2.95M (in $), with an average increase of 85.8% per quarter
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.5% return, outperforming this stock by 192.1%
NO EFFECT
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 70.6% return, outperforming this stock by 39.3%
NEGATIVE IMPACT
Price Dip
In the last 7 days, CUE stock has moved down by -4.0%

About Cue Biopharma Inc

cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci

Organisation	Cue Biopharma Inc
Headquarters	40 Guest Street, Boston, MA, United States, 02135
Industry	Health Technology
CEO	Mr. Daniel R. Passeri J.D., M.Sc.
E-voting on shares	Click here to vote

Key Management of Cue Biopharma Inc

Name	Title
Dr. Steven C. Almo Ph.D.	Co-Founder and Chairman of Scientific & Clinical Advisory Board
Mr. Colin G. Sandercock J.D., MSE	Senior VP, General Counsel & Secretary
Ms. Lucinda Warren	Chief Business Officer
Dr. Daniel G. Baker M.D., Ph.D.	Interim Chief Development Officer
Mr. Daniel R. Passeri J.D., M.Sc.	CEO, Interim Principal Financial and Accounting Officer & Director
Dr. Matteo Levisetti M.D.	Chief Medical Officer
Dr. Ronald D. Seidel III, Ph.D.	Co-Founder
Dr. Rodolfo Jose Chaparro Ph.D.	Co-Founder

FAQs

What is Cue Biopharma Inc share price today?

Cue Biopharma Inc share price today is $0.74 as on September 17, 2025 at 12:27 am IST. Cue Biopharma Inc share today touched a day high of $0.78 and a low of $0.72.

What is the 52 week high and 52 week low for Cue Biopharma Inc share?

Cue Biopharma Inc share touched a 52 week high of $1.99 on November 11, 2024 and a 52 week low of $0.45 on September 26, 2024. Cue Biopharma Inc stock price today i.e. September 17, 2025 at 12:27 am IST is trending at $0.74,which is 62.80% down from its 52 week high and 64.44% up from its 52 week low.

What is Cue Biopharma Inc's market capitalisation today?

Cue Biopharma Inc market capitalisation is $0.00T as on September 17, 2025 at 12:27 am IST.

How to invest in Cue Biopharma Inc Stock (CUE) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Cue Biopharma Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Cue Biopharma Inc Shares that will get you 2.0270 shares as per Cue Biopharma Inc share price of $0.74 per share as on September 17, 2025 at 12:27 am IST.

What is the minimum amount required to buy Cue Biopharma Inc Stock (CUE) from India?

Indian investors can start investing in Cue Biopharma Inc (CUE) shares with as little as ₹88.042 or $1 (as of September 17, 2025 at 12:39 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹880.42 in Cue Biopharma Inc stock (as per the Rupee-Dollar exchange rate as on September 17, 2025 at 12:39 am IST). Based on Cue Biopharma Inc share’s latest price of $0.74 as on September 17, 2025 at 12:27 am IST, you will get 13.5135 shares of Cue Biopharma Inc. Learn more about fractional shares .

What are the returns that Cue Biopharma Inc has given to Indian investors in the last 5 years?

Cue Biopharma Inc stock has given -95.8% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?